Fifth Circuit Pauses FDA Mifepristone Mail and Telehealth Rules
The U.S. Court of Appeals for the Fifth Circuit granted a stay of the Food and Drug Administration’s 2023 mifepristone rules, pausing nationwide the policy that had allowed the abortion pill to be prescribed by telemedicine and delivered by mail.
The three-judge panel sided with Louisiana, rolling back nationwide access to mifepristone and reinstating restrictions that could require patients to obtain the drug in person while the case continues, setting up a potential Supreme Court fight.
From the sources (8 posts)
@meidastouch🚨 NEWS: The U.S. Court of Appeals for the Fifth Circuit just rolled back nationwide access to the abortion pill mifepristone—BLOCKING telehealth prescriptions and mail delivery allowed under a 2023 Food and Drug Administration policy. A th
@scotus_wire🚨 The Fifth Circuit has granted a stay of the FDA’s 2023 mifepristone rules, pausing nationwide the policy that allowed the abortion pill to be prescribed online and mailed.
@marionawfal🚨🇺🇸 The Fifth Circuit Court of Appeals just temporarily blocked mail-order abortions involving mifepristone. The court sided with Louisiana in its case against the FDA, ruling that the in-person screening requirements for the abortion pill
@polltracker2024Politico: Appeals court approves sweeping abortion pill restrictions, teeing up SCOTUS showdown The 5th Circuit Court of Appeals on Friday rolled back access to the abortion pill mifepristone nationwide — blocking a 2023 Food and Drug Admi
@politicoAppeals court approves sweeping abortion pill restrictions, teeing up SCOTUS showdown
@justthenewsBreaking: Appeals court temporarily blocks access to mail-order abortion drugs
@polltracker2024RT @PollTracker2024: Politico: Appeals court approves sweeping abortion pill restrictions, teeing up SCOTUS showdown The 5th Circuit Court…
@axiosAppeals court limits abortion pill access